Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating long-term safety and efficacy of VX-661 (Tezacafor? actually VX-661 is a CFTR corrector) with Ivacaftor in CF patients with F508del-CFT…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Ivacaftor (ivacaftor)
• VX-661 (tezacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2020-06-16